Invivyd Inc

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Invivyd Inc advances VYD222 for COVID-19, faces regulatory challenges

Invivyd Inc's progress with VYD222 for COVID-19 prevention is promising, supported by FDA clearance and financial stability.
While facing challenges in Phase III preparation and regulatory compliance, the company's strengths in neutralizing activity and biomarker research are notable.
Opportunities lie in market growth, regulatory pathways, and enhancing biomarker expectations for VYD222's success.

Invivyd reports robust Q2 earnings, poised for COVID-19 solution success

Invivyd Inc (IVVD) showcased a strong financial performance and promising progress in commercializing VYD222 during the Q2 2023 earnings call.
While facing challenges such as trial complexities and competitive landscape, the company's strengths in financial stability, positive trial results, and experienced management team position it well for future growth.
Opportunities abound in addressing the urgent need for COVID-19 protection, exploring commercial avenues, and establishing a strong market presence with VYD222.

Invivyd Inc reports robust Q3 performance and prepares for VYD222 launch

Invivyd Inc's Q3 2023 earnings call highlighted strong financial performance, progress in the CANOPY trial for VYD222, and strategic preparations for a potential market launch in 2024.
The company's focus on addressing the urgent need for monoclonal antibodies for immunocompromised individuals aligns with significant market opportunities and positions them for future success.
While facing challenges such as regulatory submissions and competitive pressures, Invivyd Inc remains optimistic about the potential impact of VYD222 and expresses gratitude for investor support.

Invivyd Inc reports strong cash position and FDA collaborations

Invivyd Inc focuses on addressing COVID-19 challenges with high efficacy antibodies.
The company's financials show strong cash position and potential for revenue growth.
Opportunities lie in FDA collaborations, clinical trials, and expanding treatment options.
Challenges include the need for revenue generation and uncertainties in product launch.

Invivyd reports solid Q3 earnings, aims for profitability amid FDA challenges

Invivyd Inc's Q3 2024 earnings call showcased strong commercial performance with $9.3 million in PEMGARDA net product revenue. The company faces challenges with FDA warnings but aims for profitability by June 2025. Opportunities in scaling COVID-19 protection and developing potent antibodies position Invivyd for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial primary endpoint data anticipated in late 2023 or early Q1 2024 Initial primary endpoint data anticipated in late 2023 or early Q1 2024

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Hookipa Pharma Inc

Moderna

Novavax

Seelos Therapeutics

Zomedica

Amyris Inc

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

7 Biotech Stocks to Sell in September Before They Crash & Burn

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

Invivyd, Inc. (NASDAQ:IVVD ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Gabriella Linville-Engler - Investor Relations Dave Hering - Chief Financial Officer Pete Schmidt - Chief Medical Officer Conference Call Participants Maxwell Skor - Morgan Stanley Evan Wang - Guggenheim Patrick Trucchio - H.C. Wainwright Operator Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call.

Invivyd, Inc. (IVVD) Q2 2023 Earnings Call Transcript

WALTHAM, Mass, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent business highlights.

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development.

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

WALTHAM, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced additional positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate, VYD222. VYD222 is a broadly neutralizing, half-life extended mAb candidate in development for the prevention of symptomatic COVID-19 in vulnerable populations, such as immunocompromised people.

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

WALTHAM, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it has reached general alignment with the U.S. Food and Drug Administration (FDA) on a pathway to potential emergency use authorization (EUA) for VYD222 and anticipated follow-on monoclonal antibody (mAb) candidates designed to prevent symptomatic COVID-19. The company plans to leverage the pathway, which includes the use of serum neutralizing titers as a correlate of protection (surrogate of clinical efficacy) in an immunobridging approach to a pivotal clinical trial of VYD222, to rapidly generate data to support a potential VYD222 EUA for the prevention of symptomatic COVID-19. Based on FDA feedback, the use of a correlate of protection in an immunobridging approach to a pivotal EUA-directed clinical trial may be a reasonable approach for a new mAb candidate when clinical trial data from a “prototype” mAb is available, provided that the new mAb candidate: (1) is similar to the prototype mAb such that it leverages a consistent manufacturing platform and has limited structural and functional differences, and (2) has supportive nonclinical data, such as favorable in vitro neutralization data against currently circulating SARS-CoV-2 variants.

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced positive initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal antibody (mAb) candidate, VYD222. VYD222 is a broadly neutralizing, half-life extended mAb candidate in development for the prevention of symptomatic COVID-19 in vulnerable populations, such as immunocompromised people.

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 11:30 a.m. ET in New York, NY.

Invivyd to Participate at the Jefferies Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Invivyd, Inc. (NASDAQ: IVVD) on behalf of long-term stockholders following a class action complaint that was filed against Invivyd on January 31, 2023 with a Class Period from November 29, 2021 to December 14, 2021. Our investigation concerns whether the board of directors of Invivyd have breached their fiduciary duties to the company. The pl.

INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent business highlights.

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to present in a fireside chat at H.C. Wainwright's BioConnect Investor Conference on Tuesday, May 2, 2023 at 4:00 p.m. ET at the Nasdaq World Headquarters in New York, NY.

Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VYD222, a monoclonal antibody (mAb) candidate. Invivyd is developing VYD222 for the prevention of COVID-19 in vulnerable populations, such as immunocompromised people. As previously announced, VYD222 is currently being evaluated in an ongoing Phase 1 healthy volunteer clinical trial being conducted in Australia.

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

Invivyd, Inc. (IVVD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Robert Allen as chief scientific officer, and Stacy Price as chief technology and manufacturing officer.

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

NEW YORK , April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company") (NASDAQ: IVVD; ADGI). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI

NEW YORK , April 3, 2023 /PRNewswire/ -- Attention Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd") (NASDAQ: IVVD) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Invivyd Investors of a Lead Plaintiff Deadline of April 3, 2023

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 3, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Adagio” or the “Company”) (NASDAQ: IVVD) common stock between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD)

LOS ANGELES , March 31, 2023 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Adagio" or the "Company") (NASDAQ: IVVD). Class Period: November 29, 2021 – December 14, 2021 Lead Plaintiff Deadline: April 3, 2023 If you wish to serve as lead plaintiff of the Adagio lawsuit, you can submit your contact information at www.glancylaw.com/cases/Invivyd-Inc/.

IVVD Investors Have Opportunity to Lead Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/invivyd-inc-f-k-a-adagio-therapeutics-inc-loss-submission-form/?id=37893&from=4 This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.

IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023

LOS ANGELES, CA / ACCESSWIRE / March 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or "the Company") (NASDAQ:IVVD, ADGI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 29, 2021 and December 14, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 3, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses to Contact the Firm

A clinical trial generating safety, pharmacokinetics, and dosing data with the goal of providing information to allow for rapid advancement into a pivotal Phase 3 trial A clinical trial generating safety, pharmacokinetics, and dosing data with the goal of providing information to allow for rapid advancement into a pivotal Phase 3 trial

News for Invivyd Inc Stock (IVVD)